GeneCentric Launches ExpressCT Rewind to Unlock Gene Expression from Liquid Biopsy Data
DURHAM, N.C., July 8, 2026 GeneCentric has announced the launch of ExpressCT Rewind™, a retrospective fragmentomics analysis service designed...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
DURHAM, N.C., July 8, 2026 GeneCentric has announced the launch of ExpressCT Rewind™, a retrospective fragmentomics analysis service designed...
NASHIK, India, May 21, 2026 Datar Cancer Genetics (DCG) has achieved a major milestone in precision oncology after receiving...
CHICAGO — March 11, 2026 Tempus AI, Inc., a technology company focused on advancing precision medicine through artificial intelligence...
